key: cord-1042150-1xmgpr6o
authors: Bilgic, Asli; Ozcobanoglu, Salih; Bozca, Burcin Cansu; Alpsoy, Erkan
title: Livedoid vasculopathy: A multidisciplinary clinical approach to diagnosis and management
date: 2021-09-02
journal: Int J Womens Dermatol
DOI: 10.1016/j.ijwd.2021.08.013
sha: 0b81d91d9866e495e104437909ac05b21bba50e7
doc_id: 1042150
cord_uid: 1xmgpr6o

Livedoid vasculopathy (LV) is a rare, chronic, and occlusive disease of the veins supplying the upper parts of the skin. The pathogenesis of the disease is not precisely understood, and its attacks are often unpredictable but tend to worsen during the summer. LV affects women more often. This increased risk for LV in women might be related to sex-specific physiological conditions, such as pregnancy, or a higher incidence of LV-associated conditions, such as connective tissue diseases, hypercoagulable states, and venous stasis in women. The typical clinical appearance of LV consists of three main findings: livedo racemose, atrophie blanche, and skin ulcers. The purpose of this comprehensive review was to analyze LV in all aspects and mainly focus on early diagnosis for successful clinical management with a holistic and multidisciplinary approach. A detailed history, dermatological examination, and laboratory testing are essential for a diagnosis of LV. When LV is clinically suspected, a skin biopsy should be taken to confirm the diagnosis. Another critical step is to investigate the underlying associated conditions, such as connective tissue diseases, hypercoagulable states, thrombophilia, and malignancy. Unfortunately, no associated conditions can be detected in approximately 20% of all cases (idiopathic LV) despite all efforts. The diagnosis of the disease is delayed in most patients. Thus, irreversible, permanent scars appear. Early and appropriate treatment reduces pain and prevents the development of scars and other complications. Antiplatelet drugs and anticoagulants can be preferred as the first-line treatments along with general supportive measures. Other therapeutic options might be considered in unresponsive cases. Preference for refractory cases is based on availability, clinical experience, and patient-related factors (comorbidities, age, sex, and compliance). These include anabolic steroids, intravenous immunoglobulin, hyperbaric oxygen therapy, psoralen-ultraviolet A, vasodilators, fibrinolytics, immunomodulators, and immunosuppressives.

What is known about this subject regarding women and their families?

• Livedoid vasculopathy (LV) affects women more often than men (female:male ratio ∼3:2). This increased risk of LV in women might be related to sex-specific physiological conditions, such as pregnancy, or a higher incidence of LV-associated conditions, such as connective tissue diseases, hypercoagulable states, and venous stasis in women. Furthermore, various inherited coagulation abnormalities have been identified in patients with LV; thus, possible underlying genetic abnormalities must be uncovered to protect other family members. • Disfiguring complications, especially painful ulcers and scarring, could have detrimental effects on social and personal relationships and substantially deteriorate patients' quality of life. • The literature published to date is scarce and/or absent regarding specific considerations for women, the differences between sexes in terms of genetic susceptibility, therapeutic choices, and outcomes, as well as quality of life and long-term results.

• Significantly few high-quality studies have addressed problems regarding livedoid vasculopathy (LV) and therapeutic choices. • Reviews and consensus papers are of utmost importance because they show the scientific gap regarding the disease and treatment for specific groups. The current review reveals an urgent need to study and identify specific approaches regarding epidemiologic differences between the sexes, underlying conditions, quality of life, management, and long-term results for LV. • Recently, an association of LV with certain genetic variants, especially PAI-1-675 4G/5G, is highlighted. • Anticoagulants are the most reported monotherapy recently and can be selected in patients with thrombophilia and/or without significant improvement after antiplatelet treatment. Rivaroxaban is preferred due to its advantage of oral administration and the unnecessity of international normalized ratio follow-up, which increases patient compliance.

Livedoid vasculopathy (LV) is a rare, chronic, and recurrent thrombo-occlusive disease of the veins supplying the upper parts of the skin . It has had several names due to its complicated nature, including livedo vasculitis, segmental hyalinizing vasculitis, livedo reticularis with summer ulceration, Milian white atrophy, atrophie blanche en plaque, and painful purpuric ulcers with a reticular pattern of lower extremities (or PURPLE) since its first description by Milian (1929) . However, Bard and Winkelmann (1967) first used the term livedoid vasculopathy in 1967. The primary pathology is hypercoagulability, although inflammation plays a secondary role. Thus, LV is different from inflammatory vasculitis and classified as a coagulating disorder, a vasculopathy, which occurs when a thrombus forms in the arterial lu- men and compromises blood flow. LV shows a chronic course with periodic and recurrent exacerbations, often affecting the legs bilaterally ( Criado et al., 2011 ) . Definite diagnosis of LV is based on clinical manifestations and histopathological findings. LV substantially affects patients' quality of life because of its recurrent clinical course, pain, and scarring.

Early diagnosis and treatment before ulcer development can reduce pain and prevent the development of scarring, disfigurement, and other complications. Therefore, a multidisciplinary team approach involving professionals from pathology, rheumatology, hematology, radiology, cardiac surgery, infectious disease, and oncology is imperative for accurate diagnosis, identification of underlying conditions, and optimal treatment.

The literature published to date is scarce and/or absent regarding specific considerations for women, differences between the sexes in terms of genetic susceptibility, therapeutic choices and outcomes, quality of life, and long-term results. This review provides a detailed overview of epidemiology, pathogenesis, clinical features, and treatment of the disease. However, in this comprehensive review, we have mainly focused on key issues regarding diagnosis/differential diagnosis and clinical management of LV with a holistic approach. In addition, we tried to identify the research gap in the literature to form the basis for furt her research.

LV often occurs in young to middle-aged adults and affects woman more often (female:male ratio ∼2:3; Criado et al., 2011 ; Gonzalez-Santiago and Davis, 2012 ; Micieli and Alavi, 2018 ; Winkelmann et al., 1974 ) . This increased risk for LV in women might be related to sex-specific physiological conditions, such as pregnancy ( Sankar and Hinshaw, 2009 ) or a higher incidence of LVassociated conditions, such as connective tissue diseases, hypercoagulable states, and venous stasis, in women. The incidence of LV is estimated at 1:10 0,0 0 0 Criado et al., 2011 ) . Epidemiologic data also suggest that there is a 5-year delay in the adequate diagnosis and management of this condition ( Freitas et al., 2018 ) . Possible reasons for the delay in diagnosis can be that patients do not consult dermatologists in the early stages of cutaneous findings, cutaneous lesions usually initially cause minimal subjective complaints, and the current clinical picture can be confused with cutaneous findings that may accompany venous insufficiency, especially venous ulcers.

LV pathogenesis is not yet fully known. Initially, it was considered to be vasculitis. However, recent consensus suggests that changes in the local or systemic control mechanism of coagulation lead to the formation of fibrin thrombi in superficial dermal vessels. The thrombotic effect results from defects in the endothelial cell plasminogen activation, platelet dysfunction, or enhanced fibrin formation ( Vasudevan et al., 2016 ) . This dermal-vessel thrombosis leads to superficial tissue ischemia and necrosis, causing ulceration and debilitating pain ( Amato et al., 2006 ; Hairston et al., 2006 ; Vasudevan et al., 2016 ) . Low tissue perfusion further leads to poor wound healing and ineffective killing of microorganisms by leucocytes, enhancing the chance of infection ( Vasudevan et al., 2016 ) .

Patients with LV also show decreased flow-mediated vasodilation of the brachial artery, signifying endothelial dysfunction and decreased production or activity of nitrous oxide in endothelial cells, supporting the contribution of endothelial damage to LV Yang et al., 2012 ) . Therapeutic response to immunosuppressive and immunomodulatory agents and association with other autoimmune disorders also supports the involvement of autoimmunity in etiopathogenesis. Increased perfusion pressure at the ankles also appears to play an important role ( Vasudevan et al., 2016 ) . LV can be categorized as primary (idiopathic) or secondary LV, in which a known underlying condition causes the disease .

Although some mechanisms in the etiopathogenesis of LV and COVID-19-associated livedoid lesions have similar features, COVID-19 infection-causing LV has not yet been reported ( Llamas-Velasco et al., 2020 ) . Recently, COVID-19-induced recurrence of LV in a 34year-old female patient with no other comorbidities or coagulative disorders has been reported ( Valentim et al., 2021 ) .

A clinical presentation of LV is characteristic; however, biopsy is necessary to exclude other entities in the differential diagnosis and confirm LV diagnosis. Characteristic histological findings include thickening (endothelial proliferation) or hyalinized degeneration of the subintimal layer of superficial dermal vessels along with intraluminal fibrin deposits, intraluminal thrombosis, red blood cell extravasation, and scarce perivascular lymphocytic infiltration ( Bard 

Dark red violet ± ulcerated nodules on the lateral/posterior tibia, lobular panniculitis, hypersensitivity to tuberculosis Eosinophilic granulomatosis with polyangiitis ANCA + , eosinophil-rich histopathology, respiratory (rhinitis, asthma history), renal (hematuria), neurological (neuropathy, mononeuritis multiplex), cardiac (eosinophilic cardiomyopathy) and gastrointestinal (polyposis, nausea, vomiting, abdominal pain) involvement Granulomatosis with polyangiitis p-ANCA or c-ANCA positive, retiform purpura-like lesions and reticulated ulcerations, pulmonary and renal disease (glomerulonephritis) Microscopic polyangiitis p-ANCA positivity, retiform purpura-like lesions and reticulated ulcerations, dermal granuloma, mononeuritis multiplex, pulmonary and renal disease Sneddon syndrome

Livedo racemosa with cerebrovascular stroke Others in differential diagnosis of atrophie blanche Sickle cell disease, hydroxyurea ulcers, malignant atrophic papulosis, polycythemia vera, thalassemia, essential thrombocytosis, chronic myeloid leukemia ANCA, antineutrophil cytoplasmic antibody; IF, immunofluorescent; Ig, immunoglobulin; UV, urticarial vasculitis and Winkelmann, 1967 ; Haunson et al., 2012 ) . No signs of true vasculitis in the form of leukocyte infiltrate on the vessel walls are seen ( Criado et al., 2011 ; Hesse and Kutzner, 2008 ) . Thus, the histopathological findings allow clinicians to better classify LV as vasculopathy instead of immune-complex-mediated necrotizing vasculitis ( Fig. 1 ; Criado et al., 2011 ; McCalmont et al., 1992 ) .

Histopathological findings depend on the age of the lesion, and due to the focal and segmental involvement pattern of LV, classic histopathological findings may not be observed with the biopsy. Thus, attention should be given to the appropriate biopsy method . Early lesions show intraluminal hyaline thrombi in small vessels in the mid-and papillary dermis and fibrinoid materials in the vessel walls and perivascular stroma Georgesen et al., 2020 ) . Fully developed lesions show thickening and hyalinization of vessel walls with endothelial edema and proliferation, along with intraluminal fibrin thrombi, dermal sclerosis, and scarring. Multiple biopsies could be necessary for definitive diagnosis; however, some experts suggest that multiple biopsies could complicate the healing of the ulceration ( Fig. 1 ; Criado et al., 2011 ; Haunson et al., 2012 ) .

Apart from routine histopathology, direct immunofluorescence (DIF) is used. DIF demonstrates immunoglobulin deposition (multiple immunoreactants, especially C3 and immunoglobulin [Ig] M, followed by IgA, and IgG), fibrin, and complement components, although DIF findings are thought to be nonspecific and nondiagnostic ( Criado et al., 2011 ; Khenifer et al., 2009 ; Nuttawong et al., 2021 ) . In the literature, the incidence of positive DIF in patients with LV ranged from 42.9% to 100% ( Criado et al., 2014 ; Hsiao and Wu, 2010 ; Nuttawong et al., 2021 ; Schroeter et al., 1971 ; 1975 ) . Older patients and more recent lesions ( < 6 months) had a significantly higher percentage of positive DIF results for LV .

Several hereditary and acquired coagulation abnormalities are involved in LV, including polymorphisms in methylenetetrahydrofolate reductase (MTHFR), plasminogen activator inhibitor-1 (PAI-1), prothrombin, and factor V. The associations between LV and genetic abnormalities show geographical or ethnic differences. a recent systematic review investigating genetic variations identified that PAI-1-675 4G/5G was the most common, accounting for 85.26% of cases (n = 81 of 95), followed by PAI-1 A844G, MTHFR C677T, and MTHFR A1298C variants. Prothrombin G20210A and factor V G1691A were mainly present in patients with LV from Europe, North America, and South America ( Gao and Jin, 2021 ) .

Patients with LV often have a history of painful recalcitrant ulcers and whitish scars near the ankles. Burning pain is a pathognomonic prodromal symptom of this entity. Physical examination might reveal lesions in different stages of evolution. The typical clinical appearance of LV consists of three main findings: livedo racemosa, skin ulcerations, and atrophie blanche ( Fig. 1 ; .

Livedo racemosa is distinguished by vivid, erythematous to purple, network-like lines, mainly due to abnormal perfusion of cutaneous microcirculation ( Fig. 2 ) . Naturally, LV is not the only disease in which livedo racemosa can be seen; however, it is generally regarded clinically as an early manifestation of LV. Livedo reticularis and livedo racemosa (broken net pattern) are precursor lesions before ulceration.

Purpuric macules, papules, or retiform or stellate purpura (especially considered as a hallmark lesion) are other important initial findings ( Fig. 3 ) . They are often distributed on the ankles, dorsum of the feet, and the lower extremities and usually occur symmetrically. However, some studies also showed lesions on the upper extremities in a small proportion of patients ( Lee and Cho, 2020 ; Rujitharanawong et al., 2021 ) . This is followed by acute-onset, painful, and small crusted ulcers. Ulcers characterize the active stage of the disease. Excruciating pain, causing difficulties in daily life, is a clue for early diagnosis because it precedes ulceration ( Vasudevan et al., 2016 ) . Ulcers, characterized by a punched-out appearance on the perimalleolar area, heal within 3 to 4 months with atrophie blanche, small residual round or stellate porcelain- Table 2 Laboratory testing for livedoid vasculopathy

Factor V Leiden and prothrombin G20210A mutation, protein C, protein S, anti-thrombin-III deficiency, PT/PTTK, aPTT, fibrinogen, D-dimer, lupus anticoagulant, lipoprotein (a), serum homocysteine, MTHFR-C677T polymorphism, prothrombin-G20210A mutation, serum fibrinopeptide A, levels of serum complements (C3, C4), fibrinogen, plasminogen-activator inhibitor activity, antiphospholipid antibodies, cryoglobulin, cold agglutinins and cryofibrinogen, Ig light chain (kappa and lambda) levels, serum folic acid, vitamin B12 and vitamin B6 levels Connective tissue diseases (systemic lupus erythematosus, antiphospholipid antibody syndrome, rheumatoid arthritis, scleroderma, primary Sjogren's syndrome, polyarteritis nodosa, and undifferentiated connective tissue diseases) Levels of serum complements (C3, C4), ANCA, ANA, ENA, anti-Ro, anti-La, anti-CCP, rheumatoid factor, cryoglobulin, cryofibrinogen, plasminogen activator inhibitor, anti-beta-2 glycoprotein I, antiphospholipid antibodies (lupus anticoagulant), anticardiolipin antibodies (IgM and/or IgG), and IgM antiphosphatidylserine

Hematological (myeloproliferative disorders, paraproteinemia, multiple myeloma) and solid organ malignancies Ig light chain (kappa and lambda) levels, protein electrophoresis, immunofixation, lipoprotein (a) levels

Anti - white atrophic scars surrounded by hyperpigmentation and telangiectasias ( Fig. 4 ; Alavi et al., 2013 ; Criado et al., 2011 ; Weishaupt et al., 2019 ) . Although systemic involvement is not a feature of idiopathic LV, peripheral nervous system involvement (paresthesia or hyperesthesia, mononeuritis multiplex) can be seen due to multifocal thrombosis and ischemia of the vasa nervorum and is the only known extracutaneous manifestation of LV ( Criado et al., 2011 ; Tubone et al., 2013 ; Vasudevan et al., 2016 ) . A French observational study has revealed a high incidence of peripheral neuropathy (50% of patients), which has been described rarely in the existing literature ( Gan et al., 2012 ; Gardette et al., 2018 ) . Due to the limitations of conventional diagnostic techniques (electromyelography, nerve biopsy), which mainly work with large nerve fibers, a diagnosis of peripheral neuropathy requires special investigations. Gardette et al. (2018) suggested that most patients with LV have neuropathic pain that persists after healing of ulcers despite a normal electromyelography; peripheral neuropathy is probably underestimated. Nerve biopsies also reveals an ischemic process, showing that LV is not only a cutaneous but also a peripheral neurological disease ( Gardette et al., 2018 ) . Other systemic and multiorgan involvement might be present in secondary LV associated with autoimmune connective tissue disorders. A dermoscopic examination of LV could show central shallow crusted ulcers, ivory-white atrophic scar-like areas, pigment network or ivory-white structureless areas with a peripheral pigment network, and telangiectatic irregular, linear, and glomerular vessels ( Hu et al., 2017 ; Shen et al., 2019 ; Wen et al., 2020 ) .

The diagnostic criteria of LV are not well defined, and no treatment guidelines are available (except Delphi-consented expert recommendations; Alavi et al., 2013 ) . A detailed history, dermatological examination, and laboratory work-up are essential for excluding other diseases in the differential diagnosis, demonstrating associated conditions, and, therefore, a diagnosis of LV.

When LV is clinically suspected, a skin biopsy should be taken to confirm the diagnosis. A fusiform incisional biopsy containing subcutaneous fat is the most appropriate biopsy. Alternatively, a 4 to 6 mm punch biopsy may be performed. The best place for a biopsy is the edge of a new ulcer; the biopsy specimen should contain 2 to 3 mm of marginal skin and the eventual ulcer .

A differential diagnosis of other common causes of atrophie blanche should be the first step in the clinical work-up. The most common diseases to be considered in the differential diagnosis are lower extremity chronic venous insufficiency, peripheral arterial vascular disease, and vasculitis. Along with clinical signs, abnormal arterial Doppler ultrasound findings and ankle-brachial index test support the diagnosis of peripheral artery diseases. Another main differential diagnosis is cutaneous polyarteritis nodosa, which produces similar cutaneous lesions on the legs. A proper skin biopsy can distinguish LV from vasculitis.

Despite all effort s, no associated factor can be detected in approximately 20% of all cases (idiopathic LV). In the remaining patients, connective tissue disorders, malignancy, hypercoagulable states, and thrombophilia are the most important associated factors ( Table 1 ; Fig. 1 ; Alavi et al., 2013 ; Weishaupt et al., 2019 ) .

When the diagnosis is confirmed histopathologically, further review of possible underlying diseases should be undertaken. Assessment, of course, should begin with a complete history, review of systems, and physical examination to assess findings suggestive of underlying diseases. Laboratory tests for thrombophilia are recommended in all patients ( Ishibashi et al., 2009 ; Sankar and Hinshaw, 2009 ; Winkelmann et al., 1974 ) . Further examination, such as coagulating factors and their mutations, are required for hereditary or acquired thrombophilia.

Detailed laboratory research for connective tissue disorders, such as systemic lupus erythematosus, antiphospholipid antibody syndrome, rheumatoid arthritis, scleroderma, and mixed connective tissue disease, should be performed in the presence of relevant findings suggestive of these diseases. In addition, Ig kappa and lambda chain levels, protein electrophoresis, and immunofixation should be performed when paraproteinemia or solid organ cancers are suspected. Again, in the presence of an underlying in- Table 3 Therapeutic options of livedoid vasculopathy

Aspirin (acetylsalicylic acid) ( Acland et al., 1999 ; Castillo-Martínez et al., 2014 ; Criado et al., 2013 ; Drucker and Duncan, 1982 ; Gan et al., 2012 ; El Khoury et al., 2012 ; Krueger et al., 2020 ; Lee et al., 2003 ; Okada et al., 2008 ) Cyclooxygenase inhibitor; suppresses thromboxane A2 and prostaglandin I2; promotes vasodilation; prevents platelet aggregation and thrombus formation; improves ulcer healing 75-325 mg, higher doses (up to 325 mg, 3 × 1 daily) offering better results Angioedema, urticaria, gastrointestinal bleeding, Reye's syndrome, salicylism (central nervous system, tinnitus)

Pentoxifylline ( Criado et al., 2021 ; Feng et al., 2014 ; Gan et al., 2012 ; Krueger et al., 2020 ; Lee et al., 2003 ; Marzano et al., 2003 ; Meiss et al., 2006 ; Sams, 1988 ; Song et al., 2020 ; Yong et al., 2012 ) Competitive nonselective phosphodiesterase inhibitor; reduces inflammation; decreases blood viscosity; modifies red blood cell structure to reduce exocytosis; increases the inflow circulation; reduces platelet aggregation and thrombus formation 400 mg every 3 × 1 daily Dyspepsia, nausea, vomiting, abnormal liver function, alopecia

Dipyridamole ( Agirbasli et al., 2011 ; Drucker and Duncan, 1982 ; Krueger et al., 2020 ) Phosphodiesterase inhibitor; inhibits the synthesis of thromboxane A2; stimulates release of prostaglandin I2; inhibits both adenosine deaminase and phosphodiesterase, preventing the degradation of cAMP (inhibitor of platelet function and aggregation)

Initial: Dose of 50 mg, twice daily (up to75 mg 4 × 1)

Clopidogrel ( Kunzler and Chong, 2018 ) Antiplatelet agent; inhibits prostaglandin synthesis; irreversibly binds to P2Y12 ADP receptors on platelets and prevents platelet aggregation 75 mg once daily Hemorrhage, vomiting, pancytopenia, thrombotic thrombocytopenic purpura, hypersensitivity reactions Ticlopidine ( Hegemann et al., 2002 ; Okada et al., 2008 ) Prodrug that is metabolized to an active form; blocks ADP receptor that is involved in GP IIb/IIIa receptor activation leading to platelet aggregation 250 mg twice daily Aplastic anemia, thrombotic thrombocytopenia purpura, black-box warning of neutropenia, bleeding, hepatic impairment Buflomedil hydrochloride ( Criado et al., 2011 ) Antiplatelet effect; nonspecific calcium channel antagonist and alpha-blocker; increases inflow circulation Oral 150 mg, 3-4 × daily or 300 mg twice daily Flushing, headache, vertigo, dizziness, gastrointestinal discomfort Beraprost sodium ( Tsutsui et al., 1996 ) Analog of PGI2; stable, orally active prostacyclin analog with vasodilatory, antiplatelet and cytoprotective effects 120 μg/day initially and at a dose of 60 μg/d subsequently Headache, flushing, diarrhea, leg pain, and nausea Abciximab ( Vasudevan et al., 2016 ) Monoclonal ( Osada et al., 2010 ; Vasudevan et al., 2016 ) Antagonist of 5-hydroxytryptamine 2A receptor (serotonin); antiplatelet and vasodilator effects

Orally 300 mg/day Hemorrhage, thrombocytopenia, agranulocytosis, jaundice Anticoagulant Warfarin ( Browning and Callen, 2006 ; Di Giacomo et al., 2010 ; Kavala et al., 2008 ; Nakamura et al., 2011 ; Nakayama et al., 2017 ; Noda et al., 2011 ; Osada et al, 2010 ; Saoji and Madke, 2017 ; Vieira et al., 2016 ; Yoshioka et al., 2018 ) Vitamin K antagonist; inhibits vitamin-K dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors; increases fibrinolytic activity Oral/IV; 2-5 mg once daily for 1-2 days, then adjust dose based on international normalized ratio (maintained between 2 and 3) Maintenance: 2-10 mg oral/IV once daily Teratogen, bleeding, jaundice, necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions Heparin ( Abou Rahal et al., 2012 ; Di Giacomo et al., 2010 ; Francès and Barete, 2004 ) Decreases blood viscosity; increases fibrinolytic activity; increases activity of tissue plasminogen activator Dose of 5000 U/12 hr, subcutaneously Bleeding, thrombocytopenia LMWH (enoxaparin, dalteparin, nadroparin) ( Abou Rahal et al., 2012 ; Cardoso et al., 2007 ; Di Giacomo et al., 2010 ; Francès and Barete, 2004 ; Goerge et al., 2010 ; Hairston et al., 2003 ) Decreases blood viscosity; increases fibrinolytic activity Enoxaparin 40 mg/day or 100 IU/g per injection bidaily, dalteparin sodium 5000 IU/day, subcutaneously

Rivaroxaban Drabik et al., 2014 ; Drerup and Goerge, 2017 ; Evans et al., 2015 ; Franco Marques and Criado, 2018 ; Jiménez-Gallo et al., 2018 ; Kerk et al., 2013 ; Lee and Cho, 2020 ; Lee and Kim, 2016 ; Leisenring et al., 2020 ; Miguel et al., 2020 ; Weishaupt et al., 2016 ; Winchester et al., 2015 ) Direct inhibitor of factor Xa; new LMWH; decreases blood viscosity; increases fibrinolytic activity 10 mg bidaily, orally Hypermenorrhea, nose bleeding, bleeding tendency during dental procedures, and hemarthrosis

Other vitamin K antagonists (preprohormone, acenocoumarin, fluindione) ( Francès and Barete, 2004 ) Decreases blood viscosity; increases fibrinolytic activity Require monitoring international normalized ratio (maintained between 2-3)

Sulodexide ( Song et al., 2020 ) Highly purified mixture of glycosaminoglycans, including dermatan sulfate and LMWH 

Danazol/stanozolol ( Acland et al., 1999 ; Criado et al., 2015; Feng et al., 2014 ; Hsiao and Chiu, 1996 ; 1997 ; Rizzo et al., 1986 ; Wakelin et al., 1998 ) Synthetic steroids and pituitary gonadotropin inhibitors; have fibrinolytic activity Danazol: 200 mg/day or 4 mg/kg/day) for a short duration of 4-12 week Stanozolol: 4 mg/day Hirsutism, acne, steroid-like side effects, alopecia, menstrual disturbances, clitoral hypertrophy

Nifedipine ( Purcell and Hayes, 1986 ; Vasudevan et al., 2016 ) Dihydropyridine calcium channel blocker; reduces vasospasm; decreases peripheral arterial vascular resistance; increases supply of oxygen 10-20 mg 3 × 1 per day Hypotension, sinus node dysfunction, atrioventricular node dysfunction, reflex tachycardia Cilostazol ( Mendiratta et al., 2016 ) Quinolinone derivative; phosphodiesterase III inhibitor; antiplatelet agent and vasodilator 100 mg twice daily Headache, diarrhea, tachycardia, hypotension, cardiac arrhythmias Nicotinic acid (Winkelman, 1974) Niacin is a B3 vitamin; decreases levels of very low-density lipoproteins and low-density lipoproteins, while increasing levels of high-density lipoproteins 1-3 × daily Severe prolonged hypotension Alprostadil-alpha (Prostaglandin E1) ( Kawakami et al., 2007 ; Mofarrah et al., 2013 ) Direct effect on vascular smooth muscle; causes vasodilation 60 μg/day over 3 hr for 5 days, followed by a monthly infusion of 60 μg over 3 hr Apnea, bradycardia, pyrexia, hypotension İ loprost ( Magy et al., 2002 ) Synthetic analog of prostacyclin PGI2; inhibits ADP, thrombin, and collagen-induced aggregation of platelets IV via infusion pump at a rate of 0.5 ng/kg/min for 6-8 h/day (maximum tolerated dose of 2 ng/kg/min) Hypotension, headache, nausea, vomiting, and diarrhea

Ketanserin ( Rustin et al., 1989 ) S2 serotonergic receptor blocker; prevents vasoconstrictive effect of serotonin; increases cutaneous blood flow Dose of 20 mg 3 × daily Drowsiness, fatigue, headache, sleep disturbances

Colchicine ( Gan et al., 2012 ; Lee et al., 2003 ; Vasudevan et al., 2016 ) Alkaloid; inhibition of inflammation caused by tubulin disruption; anti-inflammatory effects with neutrophil inhibition Oral 0.5 mg, 2 × 3 × daily Gastrointestinal disturbance, including abdominal pain, nausea, vomiting, diarrhea Dapsone ( Acland et al., 1999 ; Gan et al., 2012 ; Irani-Hakime et al., 2008 ; Micielli and Alavi, 2018; Winkelman, 1972) Sulfone drug; anti-inflammatory effects with neutrophil inhibition; immunosuppressive and antibacterial properties Oral doses of 50-100 mg/day Nasal congestion, syncope, anemia, hallucinations

Sulfasalazine ( Bisalbutra and Kullavanijaya, 1993 ; Micielli and Alavi, 2018) Sulphapyridine metabolite; anti-inflammatory and/or immunomodulatory properties; inhibition of platelet aggregation by 5-aminosalicylic acid prevents cytokine release from mononuclear cells 500 mg, 3 × 1 daily, orally Headache, facial edema, paresthesia of the lips, nausea, rash, itchiness, metallic taste

Doxycycline ( Keller et al., 2008 ) Second-generation tetracycline antibiotic; anti-inflammatory and antimicrobial, bacteriostatic effects by inhibition of protein synthesis Dose of 100 mg twice daily Tooth enamel hypoplasia, yellow-gray discoloration of teeth, gastrointestinal irritation, esophagitis Hydroxychloroquine ( Gan et al., 2012 ; Irani-Hakime et al., 2008 ; Keller et al., 2008 ; Vasudevan et al., 2016 ) Aminoquinoline; affects function of lysosomes in humans; inhibits antigen presentation of the cell; reduces inflammatory response Up to 0.6 mg/kg/day Headache, drowsiness, visual disturbances, convulsions, rhythm, conduction disorders including QT prolongation, torsades de pointes, ventricular tachycardia, ventricular fibrillation Immunosuppressants Prednisolone Criado et al., 2011 ; Gan et al., 2012 ; Marzano et al., 2003 ; Micieli et al., 2018) Anti-inflammatory action; antifibrinolytic effect; immunosuppressive effect 0.5-1 mg/kg/day (prednisolone or equivalent)

Azathioprine Criado et al., 2011 ; Gan et al., 2012 ; Micieli et al., 2018) Prodrug of 6-mercaptopurine; inhibits purine synthesis along with inhibition of B and T cells 2-3 mg/kg/day Bone marrow hypoplasia, hepatotoxicity, infection

Cyclophosphamide Criado et al., 2011 ; Gan et al., 2012 ; Micieli et al., 2018) Alkylating agent; cytotoxic effect due to cross-linking of strands of DNA and RNA; inhibition of protein synthesis; immunosuppressive effect 1.5-2.5 mg/kg/day Neutropenia, alopecia, nausea, vomiting, diarrhea, sterility, birth defects, mutations, cancer Cyclosporine Criado et al., 2011 ; Micieli et al., 2018) Calcineurin inhibitor; potent immunomodulatory agent; suppresses lymphocyte activity; inhibits expression of tissue factor of monocytes, which is a vital component in triggering the coagulation cascade 3-5 mg/kg/day Hypertrichosis, gingival hyperplasia, nephrotoxicity, hypertension

Folic acid ( Anderson et al., 2013 ; Errichetti and Stinco, 2016 ; Meiss et al., 2006 ) Required for homocysteine remethylation; necessary to maintain adequate plasma homocysteine and serum folate levels 5 mg/day Abdominal cramps, diarrhea, sleep disorders, irritability, confusion, stomach upset Vitamin B12/B6 ( Anderson et al., 2013 ; Errichetti and Stinco, 2016 ; Meiss et al., 2006 ) Additional supplementation along with folic acid Vitamin B6 (1500 μg/day) and vitamin B12 Nausea, stomach upset, diarrhea, drowsiness, flushing, numbness/tingling Miscellaneous ( Amital et al., 2000 ; Bounfour et al., 2013 ; Kim et al., 2015 ; Kofler et al., 2021 ; Kreuter et al., 2004 ; Monshi et al., 2014 ; Oravec et al., 1995 ; Ozden et al., 2020 ; Pitarch et al., 2005 ; Ravat et al., 2002 ; Tuchinda et al., 2011 ) Acts by inhibiting Fc receptor function in macrophages, T cells, and B cells, leading to decreased cytokine production; reduces immune complex deposition in small vessels; inhibits thromboxane synthetase; decreases vasoconstriction Monthly infusions in the dose of 0.4-2 g/kg over 2-3 consecutive days Allergic reactions, headache, flushing, chills, myalgia, wheezing, tachycardia, hypotension Hyperbaric oxygen ( Banham, 2013 ; Bhutani et al., 2012 ; Bollmann et al., 2011 ; Fernandes, 2009 ; Juan et al., 2006 ; Ray et al., 2015 ; Verma, 2013 ; Yang et al., 2003 ) Enhances tissue oxygenation and microvascular perfusion by stimulating nitric oxide synthesis; accelerates angiogenesis and fibrinolysis; accelerates fibroblast proliferation; diminishes tissue reperfusion injury; increases growth of granulation tissue; bacteriostatic and bactericidal effects Pure oxygen or 100% 1.5-2 hr, 1-3 × daily Lung damage, changes in vision, oxygen poisoning Psoralen plus ultraviolet A ( Choi and Hann, 1999 ; Lee et al., 2001 ; Tuchinda et al., 2005 ) Decreases ability of lymphocytes to respond to cytokine production; induces release of immunosuppressive factors 2-3 × per week Sunburn-like reaction, phototoxic erythema, skin ageing and skin cancer Rituximab ( Zeni et al., 2008 ) Monoclonal anti-CD20 antibody 1.0 g, two infusions, 14 days apart Neonatal harm, infection risk, severe immunosuppression Antitumor necrosis factor (etanercept) ( Gao and Jin, 2020 ) Anti-inflammatory properties; act mainly by close interaction between various inflammatory cytokines and coagulation 25-50 mg once a week for 12 consecutive weeks Infection risk, immunosuppression ADP, adenosine diphosphate; cAMP; IV, intervenous; LMWH, low molecular weight heparin; PGI2, prostaglandin I2 fection suspicion, tests for hepatitis and HIV infection should be performed ( Table 2 ) .

Treatment of LV is very challenging for physicians. Because the incidence of LV is relatively low, there are no large series of studies on its treatment. Therefore, the level of evidence is not high, and treatment recommendations are generally based on case series, small clinical trials, or expert recommendations. No single therapeutic approach is effective for all patients. Furthermore, there are no predictive clinical or biologic indicators for the severity or frequency of LV flares. For this reason, many options are often used in combination. Moreover, there is no fixed endpoint for treatment in patients who respond to treatment. Once the ulcer has healed, treatment may be discontinued; however, long-term treatment may be necessary to maintain healing. Treatment selection can be based on cost, adherence, patient comorbidities, and clinical experience. The main treatment options are presented in Table 3 . Our approach is reviewed herein, and the therapeutic algorithmic approach is presented in Figure 5 .

Although the best approach to treatment is unclear, general measures (e.g., wound care, smoking cessation, compression, and pain management) are important components of LV therapy along with pharmacological treatment. Wound care should include maintaining a moist wound environment and controlling superinfection. Patients should be encouraged to stop smoking because of the negative effects of smoking on wound healing. Compression therapy is also helpful in patients with venous insufficiency. Improvement may be due to the stimulating effect of compression on fibrinolytic activity and controlling edema. Pain secondary to livedoid vasculopathy can be severe. Nonsteroidal anti-inflammatory drugs, such as indomethacin or acetaminophen, can be used. Tricyclic antidepressants, gabapentin, pregabalin, or carbamazepine may be preferred for neuropathic pain and are valuable for patients with persistent painful ulcerations Micieli and Alavi, 2018 ) .

The first-line therapeutic step is antiplatelet therapy (aspirin, dipyridamole, and pentoxifylline). Aspirin (300 mg once daily) is preferred, especially as the initial therapy for patients without an identified thrombophilia and/or with sickle cell trait. Tolerability, wide availability, and low cost are important advantages of this compound. Dipyridamole and pentoxifylline (600 mg twice daily) can be favored in combination with aspirin in unresponsive cases or alone in patients who cannot tolerate aspirin. In patients with identified thrombophilia and/or without significant improvement after antiplatelet treatment, anticoagulants can be used. Low molecular weight heparin (1 mg/kg/d) or rivaroxaban (2 × 15 mg in the first week, then continue with 20 mg once daily) are typically used at our center. Anticoagulants were the most reported monotherapy in a recent systematic review by Micieli and Alavi (2018) . Rivaroxaban is often the treatment of choice in recent years due to the advantage of oral administration and the unnecessity of international normalized ratio follow-up, which increases patient compliance.

Anabolic steroids (prednisolone and equivalents, danazol 4 mg/kg/d) were the second most used and effective treatment in clinical trials. They inhibit coagulation while increasing fibrinolysis. They can be the next step, especially in patients with connective tissue diseases, hyperfibrinogenemia, and other occlusive conditions. Systemic steroids can also be added to the main treatment to achieve rapid disease control at any timepoint.

In resistant cases, preference for therapeutic choices is based on availability, clinical experience, and patient-related factors (comorbidities, age, sex, compliance). Intravenous Ig, hyperbaric oxygen treatment (1.5-2-hour sessions, three times daily for 3-4 weeks) and fibrinolytics (recombinant tissue plasminogen activator, 10 mg/d for 14 days) have also been reported to be effective alternatives. These treatments would be more suitable for refractory LV due to high cost and difficulties in patient compliance. All other therapeutic options are summarized in Table 3 . Hydroxychloroquine in patients with systemic lupus erythematosus and antiphospholipid antibody syndrome, and colchicine in patients with vasculitis can be reasonable options in combination with antiplatelet and/or anticoagulant therapies. Vasodilators (used as maximum tolerated dose), anti-inflammatory agents, immunosuppressives, and psoralen-ultraviolet A could be used as third-line options. Vitamin supplements, especially folic acid and vitamin B12/B6, are required for homocysteine remethylation; thus, they can be added to treatment. All these agents are used often in combination with antiplatelets and anticoagulants Micieli and Alavi, 2018 ) .

LV is associated with a variety of underlying conditions, and no single etiology has been identified. Since the therapeutic approach should be modified according to etiopathogenetic mechanisms, possible systemic associations should be investigated. Several therapeutic options with different success rates are being used. However, randomized controlled trials with a high evidence level should be performed to determine the best therapeutic approach in the treatment of LV. Furthermore, a multidisciplinary approach is necessary for effective and proper treatment.

None.

None.

Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: Treatment with lowmolecular-weight heparin

Livedoid vasculitis: A manifestation of the antiphospholipid syndrome?

Enhanced functional stability of plasminogen activator inhibitor-1 in patients with livedoid vasculopathy

Livedoid vasculopathy: An in-depth analysis using a modified Delphi approach

Idiopathic atrophie blanche

Use of intravenous immunoglobulin in livedo vasculitis

Response of serum and red blood cell folate concentrations to folic acid supplementation depends on methylenetetrahydrofolate reductase C677T genotype: Results from a crossover trial

Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) and prothrombin G20210A heterozygosity: Response to t-PA therapy

Livedoid vasculopathy successfully treated with hyperbaric oxygen

Livedoid vasculopathy managed with hyperbaric oxygen therapy

Sulfasalazine in atrophie blanche

Livedoid vasculopathy: fast involution after anticoagulant and hyperbaric oxygen therapy

Intravenous immunoglobulins in difficult-to-treat ulcerated livedoid vasculopathy: Five cases and a literature review

Warfarin therapy for livedoid vasculopathy associated with cryofibrinogenemia and hyperhomocysteinemia

Livedoid vasculopathy and hypercoagulability in a patient with primary Sjogren's syndrome

Livedoid vasculopathy (LV) associated with sticky platelets syndrome type 3 (SPS type 3) and enhanced activity of plasminogen activator inhibitor (PAI-1) anomalies

Treatment application of rivaroxaban in Chinese patients with livedoid vasculopathy

Livedo reticularis and livedoid vasculitis responding to PUVA therapy

Livedoid vasculopathy: An intringuing cutaneous disease

Unilateral livedoid vasculopathy associated with involutional phase of cutaneous infantile hemangioma: The connection to coagulation disorders

Direct immunofluorescence findings and thrombophilic factors in livedoid vasculopathy: how do they correlate?

Livedoid vasculopathy in 75 Brazilian patients in a single-center institution: Clinical, histopathological and therapy evaluation

A phase II multicenter trial with rivaroxaban in the treatment of livedoid vasculopathy assessing pain on a visual analog scale

Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator

Frequency of thrombophilia determinant factors in patients with livedoid vasculopathy and treatment with anticoagulant drugs-A prospective study

Prevention of livedoid vasculopathy recurrence by prolonged administration of rivaroxaban

Antiplatelet therapy in atrophie blanche and livedo vasculitis

Livedoid vasculopathy associated with sickle cell trait: Significant improvement on aspirin treatment

Recalcitrant livedoid vasculopathy associated with hyperhomocysteinaemia responding to folic acid and vitamins B6/B12 supplementation

Successful treatment of livedoid vasculopathy with rivaroxaban

Livedoid vasculopathy: clinical features and treatment in 24 Chinese patients

Hyperbaric medicine

Difficult management of livedoid vasculopathy

Alves Batista Morita TC, Cajas García MS. The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): Four case reports successfully treated with rivaroxaban

Livedoid vasculopathy: A compelling diagnosis

A ten-year retrospective study on livedo vasculopathy in Asian patients

Livedoid vasculopathy and its association with genetic variants: A systematic review

Efficacy of an anti-TNF-alpha agent in refractory livedoid vasculopathy: A retrospective analysis

Livedoid vasculopathy: A French observational study including therapeutic options

Retiform purpura: A diagnostic approach

Livedoid vasculopathy in a pediatric patient with elevated lipoprotein(a) levels: Prompt response to continuous low-molecular-weight heparin

Update of management of connective tissue diseases: Livedoid vasculopathy

Treatment of livedoid vasculopathy with low-molecular-weight heparin: Report of 2 cases

Livedoid vasculopathy: Further evidence for procoagulant pathogenesis

Livedoid vasculopathy: Review of pathogenesis, clinical presentation, diagnostic workup, and treatment

Livedoid vasculitis with ulcerations: The role of antithrombin III deficiency and its therapeutic consequences

Therapeutic use of low molecular weight heparin for capillaritis alba

Livedoid vasculitis. Response to low-dose danazol

Low-dose danazol in the treatment of livedoid vasculitis

Distinct pattern of direct immunofluorescence in livedoid vasculopathy

Dermoscopic features of livedoid vasculopathy

Livedoid vasculopathy associated with combined prothrombin G20210A and factor V (Leiden) heterozygosity and MTHFR C677T homozygosity

Livedoid vasculopathy with underlying subcutaneous necrotizing venulitis in an asymptomatic hepatitis B virus carrier: Is livedoid vasculopathy a true nonvasculitic disorder?

Treatment of livedoid vasculopathy with rivaroxaban: A potential use of new oral anticoagulants for dermatologists

Dramatic response of livedoid vasculitis to tissue plasminogen activator (tPA)

Livedoid vasculopathy: Long-term follow-up results following hyperbaric oxygen therapy

A case of livedoid vasculopathy associated with factor V Leiden mutation: Successful treatment with oral warfarin

Therapeutic effect of lipoprostaglandin E1 on livedoid vasculitis associated with essential cryoglobulinaemia

Livedoid thrombotic vasculopathy responding to doxycycline therapy

Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy

Livedoid vasculitis associated with a double heterozygous Factor V Leiden and prothrombin G20210A gene mutation

Pulsed intravenous immunoglobulin therapy in refractory ulcerated livedoid vasculopathy: Seven cases and a literature review

Tissue plasminogen activator for treatment of livedoid vasculitis

Intravenous immunoglobulin therapy in livedoid vasculopathy: Retrospective observation of clinical outcome and patient's activity level

Pulsed intravenous immunoglobulin therapy in livedoid vasculitis: An open trial evaluating 9 consecutive patients

Primary livedoid vasculopathy associated with mononeuritis multiplex

Ulcerative livedoid vasculopathy responding to clopidogrel

Livedoid vasculitis responding to PUVA therapy

Clinical profile and treatment outcome of livedoid vasculitis: A case series

Case series of recalcitrant livedoid vasculopathy treated with rivaroxaban

Livedoid vasculopathy in Koreans: Clinical features and response to rivaroxaban treatment

Successful treatment of painful cutaneous vasculopathy with rivaroxaban in a patient with systemic lupus erythematosus

Thrombotic occlusive vasculopathy in a skin biopsy from a livedoid lesion of a patient with COVID-19

Livedoid vasculopathy with combined thrombophilia: Efficacy of iloprost

Widespread livedoid vasculopathy

Livedo vasculitis: Vasculitis or thrombotic vasculopathy?

Livedoid vasculopathy. The role of hyperhomocysteinemia and its simple therapeutic consequences

Cilostazol: A novel agent in recalcitrant livedoid vasculopathy

Treatment for livedoid vasculopathy: A systematic review

Chronic leg ulcerations associated with livedoid vasculopathy successfully treated with rivaroxaban

Les atrophies cutanees syphilitiques

Treatment of livedoid vasculopathy with alprostadil (PGE-1): Case report and review of published literature

Efficacy of intravenous immunoglobulins in livedoid vasculopathy: Long-term follow-up of 11 patients

Failure of livedoid vasculitis to respond to tissue plasminogen activator

Livedoid vasculopathy; favorable clinical response with low dose warfarin

Livedoid vasculopathy and popliteal artery occlusion in a patient with protein S deficiency

Severe livedoid vasculopathy associated with antiphosphatidylserine-prothrombin complex antibody successfully treated with warfarin

Direct immunofluorescence findings in livedoid vasculopathy: A 10-year study and literature review

A case of widespread livedoid vasculopathy with pain but no systemic symptoms

Normal human polyspecific immunoglobulin G (intravenous immunoglobulin) modulates endothelial cell function in vitro

Case of livedoid vasculopathy with peripheral neuropathy successfully treated with low-dose warfarin

Intravenous immunoglobulin in resistant livedoid vasculopathy: Analysis of a case series

Treatment of livedoid vasculopathy with short-cycle intravenous immunoglobulins

Nifedipine treatment of idiopathic atrophie blanche

Response of livedoid vasculitis to intravenous immunoglobulin

Livedoid vasculopathy with hyperhomocysteinemia responding to hyperbaric oxygen therapy

Fibrinolysis induced by danazol

Livedoid vasculopathy: Clinical course and long-term outcome in Asian patients with a review of the literature

Chronic leg ulceration with livedoid vasculitis, and response to oral ketanserin

Livedo vasculitis. Therapy with pentoxifylline

Livedoid vasculopathy and pregnancy

Use of low-dose oral warfarin in three cases of livedoid vasculopathy

Immunofluorescence of cutaneous vasculitis associated with systemic disease

Livedo vasculitis (the vasculitis of atrophie blanche). Immunohistopathologic study

Dermoscopy in China: Current status and future prospective

A case of livedoid vasculopathy successfully treated with sulodexide

Successful treatment of livedo vasculitis with beraprost sodium: A possible mechanism of thrombomodulin upregulation

Livedoid vasculopathy associated with peripheral neuropathy: A report of two cases

Successful long-term use of intravenous immunoglobulin to treat livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity

Refractory livedoid vasculitis responding to PUVA: A report of four cases

Recrudescence of livedoid vasculopathy induced by COVID-19

Livedoid vasculopathy: A review of pathogenesis and principles of management

Livedoid vasculopathy managed with hyperbaric oxygen therapy

Livedoid vasculopathy-A challenging disease

Intractable livedoid vasculopathy successfully treated with hyperbaric oxygen

Association between peripheral vascular endothelial dysfunction and livedoid vasculopathy

Livedoid vasculopathy and its association with factor V Leiden mutation

Systemic lupus erythematosus with refractory ulcerated livedoid vasculopathy: Successful treatment with intravenous immunoglobulin and warfarin

Livedoid vasculitis with anticardiolipin antibodies: Improvement with danazol

Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): A multicentre, single-arm, open-label, phase 2a, proof-of-concept trial

Characteristics, risk factors and treatment reality in livedoid vasculopathy-A multicentre analysis

Clinical and dermoscopic features of livedoid vasculopathy

Response of livedoid vasculopathy to rivaroxaban

Clinical studies of livedoid vasculitis (segmental hyalinizing vasculitis)

Successful use of rituximab in a patient with recalcitrant livedoid vasculopathy